within Pharmacolibrary.Drugs.ATC.R;

model R03AK10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.03,
    Cl             = 1.8,
    adminDuration  = 600,
    adminMass      = 0.025,
    adminCount     = 1,
    Vd             = 0.165,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Vilanterol and fluticasone furoate is a combination inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Vilanterol is a long-acting beta2-adrenergic agonist (LABA), while fluticasone furoate is an inhaled corticosteroid. The drug is approved and regularly used in clinical practice for long-term management of airway obstruction.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from published studies in healthy adult subjects for inhaled administration of vilanterol 25 mcg and fluticasone furoate 100 mcg once daily.</p><h4>References</h4><ol><li><p>Chen, X, et al., &amp; Allen, A (2015). Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. <i>Pharmacotherapy</i> 35(6) 586–599. DOI:<a href=&quot;https://doi.org/10.1002/phar.1598&quot;>10.1002/phar.1598</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26059225/&quot;>https://pubmed.ncbi.nlm.nih.gov/26059225</a></p></li><li><p>Li, Y, et al., &amp; Ma, P (2019). Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. <i>Clinical pharmacology in drug development</i> 8(6) 721–733. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.626&quot;>10.1002/cpdd.626</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30427594/&quot;>https://pubmed.ncbi.nlm.nih.gov/30427594</a></p></li><li><p>Siederer, S, et al., &amp; Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. <i>European journal of drug metabolism and pharmacokinetics</i> 41(6) 743–758. DOI:<a href=&quot;https://doi.org/10.1007/s13318-015-0303-4&quot;>10.1007/s13318-015-0303-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26474864/&quot;>https://pubmed.ncbi.nlm.nih.gov/26474864</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AK10;
